OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential	381
Network pharmacology: curing causal mechanisms instead of treating symptoms	319
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic	275
Organ-on-a-Chip: A New Paradigm for Drug Development	245
NLRP3 and pyroptosis blockers for treating inflammatory diseases	219
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19	212
Causes and Consequences of Snake Venom Variation	196
Can Activation of NRF2 Be a Strategy against COVID-19?	157
In Vitro and Animal Models for SARS-CoV-2 research	151
A Perspective on Multi-target Drugs for Alzheimer’s Disease	150
Paving the Road for RNA Therapeutics	144
Tryptophan Metabolism as a Pharmacological Target	142
Emerging New Concepts of Degrader Technologies	119
Drug Repurposing for Rare Diseases	112
Metformin and Systemic Metabolism	110
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2	100
Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery	98
Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation	94
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics	91
Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor	90
Iron metabolism: pathophysiology and pharmacology	90
Physiological and pharmacological modulation of BAX	89
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	81
Update and latest advances in antiretroviral therapy	77
Targeting the Immune System for Ischemic Stroke	75

AKAP Signaling Islands: Venues for Precision Pharmacology	72
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades	70
Progranulin as a therapeutic target in neurodegenerative diseases	70
Peptide–drug conjugate-based novel molecular drug delivery system in cancer	69
Nrf2 for cardiac protection: pharmacological options against oxidative stress	68
Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance	63
Recent breakthroughs and future directions in drugging aquaporins	62
Disrupting 3D printing of medicines with machine learning	61
Tackling TAMs for Cancer Immunotherapy: It’s Nano Time	61
Inhaled RNA Therapy: From Promise to Reality	60
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality	58
Deciphering the TCR Repertoire to Solve the COVID-19 Mystery	56
Advances and challenges in therapeutic targeting of NRF2	55
Circulating tumor cells in precision medicine: challenges and opportunities	52
Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy	50
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics	50
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment	49
Carbon Monoxide: from Poison to Clinical Trials	46
Affinity Hydrogels for Protein Delivery	44